Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 3/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14495000 | 0.89 | MTNR1A (0.58) | MTNR1AMTNR1BHSD17B10SMN1; SMN2 | |
| SCHEMBL14495036 | 0.88 | NQO2 (0.45) | MTNR1AMTNR1BALDH1A1KDM4ETAAR1 | |
| SCHEMBL12192721 | 0.83 | PTGER1 (0.50) | MTNR1AMTNR1BALDH1A1KDM4ETAAR1 | |
| SCHEMBL13727558 | 0.83 | MTNR1A (0.44) | MTNR1AMTNR1BALDH1A1KDM4ETAAR1 | |
| SCHEMBL153172 | 0.78 | TAAR1 (0.54) | MTNR1AMTNR1BALDH1A1KDM4ETAAR1 | |
| SCHEMBL17149982 | 0.76 | ALDH1A1 (0.54) | MTNR1AMTNR1BALDH1A1KDM4ETAAR1 | |
| SCHEMBL9186971 | 0.75 | MTNR1A (0.63) | MTNR1AMTNR1BALDH1A1KDM4ETAAR1 | |
| SCHEMBL14494995 | 0.74 | MTNR1A (0.58) | MTNR1AMTNR1BKDM4EHPGDHSD17B10 | |
| SCHEMBL149945 | 0.74 | HSD17B10 (0.53) | ALDH1A1KDM4ETAAR1HPGDATM | |
| SCHEMBL11211183 | 0.74 | AOC3 (0.41) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394789-B2 | (Dihydro)pyrrolo[2,1-α]isoquinolines | MSD OSS B.V. (NL) | 2013-03-12 | — | — | US | disclosed |
| US-20110039832-A1 | DIHYDRO)PYRROLO[2,1-A]ISOQUINOLINES | N.V. ORGANON (NL) | 2011-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039832-A1 | DIHYDRO)PYRROLO[2,1-A]ISOQUINOLINES | PKD2, PKD1, CATSPER1 | MTNR1A 2220/4885MTNR1B 1457/4885ALDH1A1 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.